Silvana de Castro Faria

Statistics

Publications

Citations

729

H-Index

Active since

2004

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Silvana de Castro Faria is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer pharmacology.

Publications per year

2004–2013

Publications

<b>CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment:</b> A Quantitative Analysis Correlated with FDG PET Findings

Haesun Choi, C Charnsangavej, Silvana de Castro Faria et al. · American Journal of Roentgenology · 2004 · 456 citations

Medicine, Oncology, Radiology +17

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Anas Younes, Jorge Romaguera, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2012 · 139 citations

Medicine, Oncology, Pharmacology +13

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Yasuhiro Oki, Daniela Buglio, Michelle A. Fanale et al. · Clinical Cancer Research · 2013 · 110 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, Amanda Copeland, Michelle A. Fanale et al. · Blood · 2011 · 13 citations

Medicine, Oncology, Pharmacology +16

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, Michelle A. Fanale, Peter McLaughlin et al. · Blood · 2009 · 11 citations

Medicine, Oncology, Pharmacology +14

1–5 of 5